Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRIANGLE trial in untreated generalized mantle cell lymphoma
NL-OMON59915Phase 3Completed
- Sponsor
- LMU Klinikum
- Start
- Oct 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of ibrutinib in mantle cell lymphoma (MCL) (3 arms), sponsored by LMU Klinikum. Primary endpoint: Failure-free survival. Started Oct 2017; status: completed.
02
Drugs
ibrutinib
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on NL-OMON59915.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59915.